AI as a Safety-Net Reader for Mammograms Classified as Normal or Benign in the French Screening Program.
Authors
Affiliations (4)
Affiliations (4)
- Imagerie Hôpital Privé Mermoz, 55 Avenue Jean Mermoz, 69008 Lyon, France.
- Centre Radiologie République, Clermont-Ferrand, France.
- Centre Régional de Coordination des Dépistages des Cancers en Auvergne Rhône-Alpes, Lyon, France.
- Medical Imaging Department, CHU Montpellier, Montpellier, France.
Abstract
In the French national breast cancer screening program, second reading is performed only for mammograms interpreted as negative (BI-RADS 1-2) at first reading, representing a unique screening workflow in Europe. This retrospective study assessed whether artificial intelligence (AI) could identify a subgroup of negative screening mammograms that could safely bypass second reading. A total of 55,589 screening mammograms from 42,419 women aged 50-74 years (January 2015-December 2019) initially classified as BI-RADS 1-2 were analyzed. Second-reading outcomes were compared with those of a commercial AI system using a predefined binary threshold (≥ 5). Among these examinations, 183 of 55,589 (0.33%) were recalled at second reading, yielding 12 cancers (positive predictive value, 6.6%; cancer detection rate, 0.22 per 1,000 examinations). AI classified 42,606 of 55,589 (76.6%) examinations as low risk (≤ 4) and 12,983 of 55,589 (23.3%) as non-low risk (≥ 5). One cancer was detected in the AI-low group (1 of 55,589 [0.002%]) compared with 11 in the AI-nonlow group (11 of 55,589 [0.020%]; <i>P</i> < .001). Interval cancer rates were higher in the AI-non-low group than in the AI-low group (2.16 vs 0.47 per 1,000 examinations). These findings suggest that excluding AI-low examinations from second reading could reduce workload by approximately 77% while focusing radiologist review on higher-risk cases; prospective validation is needed. AI triage could potentially reduce second-reading workload by approximately 77% in the French breast cancer screening program, despite a small but measurable risk of missed cancers and the need for governance.